The revolt inside the American Diabetes Association has hardened. More than 200 members have called for the resignation of the organization's chief executive and chief scientific officer, an independent investigation into the June expulsion of five researchers from its annual meeting, a full apology, and the restoration of editorial independence at Diabetes Care, the ADA's flagship journal. The organization has asked for patience while an audit and governance committee prepares a report. The dispute is now less about a single bad decision at a conference than about what the ADA is willing to trade away, and for what.
A telling detail sits inside the CEO's apology. In explaining the organization's posture, Charles Henderson tied the ADA's conduct to its commitment to advocate for robust NIH funding. That connection, between suppressing members who criticized the administration and protecting the federal money the organization depends on, is the key to the whole episode. It points at a conflict of interest that any funder-dependent scientific body faces, and it becomes especially clear when you set the ADA's current behavior against how the same organization acted a decade ago, when defending scientific independence cost it nothing.
The same principle, two opposite postures
Go back to 2015. The ADA was then defending the editorial integrity of another of its journals, Diabetes, against a defamation lawsuit brought by a São Paulo researcher, Mario Saad, after the journal raised concerns about his work. The researcher argued the journal was persecuting him; the ADA stood behind its journal's editorial judgment and defended its right to make it. In that fight, the ADA was a defender of editorial independence, willing to face a lawsuit rather than let an aggrieved outsider dictate what its journal could say.
Now look at 2026. The ADA is not defending editorial independence against an outside threat. It is the entity that suppressed an editorial, one published in its own journal, and its members are demanding that it restore the editorial independence it is accused of compromising. On the identical underlying principle, whether a scientific journal and its authors get to speak without institutional interference, the ADA has flipped from defender to violator in the space of a decade. The question worth asking is what actually changed, because the answer is not the organization's stated values, which still invoke scientific integrity. It is the source of the threat, and what defending the principle would cost.
Principle is only tested when defending it is expensive
Here is the pattern the contrast exposes. In 2015, defending editorial independence was cheap for the ADA and aligned with its interests. The threat came from an outside litigant, standing firm cost the organization little beyond legal expense, and defending its journal made the ADA look principled at no real strategic risk. Defending a principle when doing so costs you nothing, and even burnishes your reputation, is easy, and it does not reveal much about how deeply the principle is held.
In 2026, the situation inverted. The threat to editorial independence does not come from an outside adversary the ADA can safely resist. It comes from the ADA's own interest in staying on good terms with the federal government that funds much of the diabetes research the organization exists to support. Defending its members' right to publish criticism of that government would cost the ADA something real: the risk of antagonizing the body that controls the money. Faced with a case where upholding the principle carried a price, the organization appears to have set the principle aside. That sequence, defending independence when it is free and abandoning it when it is costly, is the signature of behavior driven by interest rather than principle. A commitment that holds only when it is convenient was never really a commitment; it was an alignment that happened to coincide with principle until the two diverged.
The conflict of interest hiding in plain sight
Strip the episode to its structure and it is a straightforward conflict of interest, and naming it that way clarifies everything without requiring any position on the politics involved. An organization that depends on government funding has an institutional incentive to avoid antagonizing the government. That incentive sits in direct tension with the organization's role as a scientific body, which is supposed to defend open, evidence-based inquiry and the freedom of its members to follow and voice the evidence wherever it leads, including toward conclusions a funder dislikes.
Most of the time those two things coexist quietly, because advocating for a field and defending its freedom point the same way. They collide when defending the freedom means criticizing the funder. At that point the organization must choose between protecting the money and protecting the independence, and the ADA's own CEO framed the organization's conduct in terms of protecting the money. This is not a partisan observation, and it does not depend on what one thinks of the administration or its funding decisions, which are contested questions this analysis takes no side on. The structural point holds for any funder and any administration: a scientific organization financially dependent on a party it may need to criticize has a conflict of interest, and how it resolves that conflict reveals whether it is ultimately a scientific body or a client of its funder. The members demanding restoration of editorial independence are, in effect, demanding the organization resolve the conflict in favor of its scientific mission rather than its funding relationship.
The trade is self-defeating
The sharpest problem with choosing funding over independence is that the choice tends to destroy the thing the funding is supposed to support. The value of a scientific and patient-advocacy organization rests substantially on its credibility, on the belief that its research, guidance, and advocacy reflect evidence rather than the preferences of whoever pays. An organization that visibly suppresses its own scientists to keep a funder happy has, by that act, advertised that its outputs may bend to that funder's wishes. If the ADA will muzzle its members to avoid displeasing the government, why should anyone be confident its scientific positions are independent of what the government wants to hear?
So protecting the funding by suppressing dissent corrodes the independence that makes the organization's science worth funding in the first place. The credibility and the money are not separable goods to be traded against each other; the credibility is much of what justifies the money. Spend the credibility to protect the money and you undermine the case for the money. And the episode has already demonstrated the self-defeat in real time: the suppression, not the editorial, became the damaging national story, inflicting far more reputational harm on the ADA than letting five researchers hand out a journal article ever would have. The organization paid a large reputational cost to protect a funding relationship, and in doing so made itself look exactly like the captured institution its critics now accuse it of being.
The ADA's strongest defense, taken seriously
Fairness requires the best version of the ADA's position, because it is not simply cowardice and the tradeoff is genuine. The ADA is a patient-advocacy organization serving, by its own count, more than 155 million Americans living with diabetes or prediabetes, and robust federal research funding genuinely serves those patients by advancing the science that improves their lives. From that vantage, avoiding gratuitous antagonism of the body that controls that funding is arguably a responsible strategic choice in service of the mission, not a betrayal of it. An organization that picks unnecessary fights and loses its funding helps no one, and there is a coherent argument that the ADA's first duty is to protect the research pipeline for patients, even at some cost to the expressive freedom of individual members at a conference.
That argument deserves to be weighed rather than dismissed, and reasonable people can land on different sides of it. But it runs into the self-defeat problem above, and into a matter of degree. There is a difference between prudently choosing which battles to fight and having your own members escorted out by police for distributing a peer-reviewed editorial from your own journal, then delaying publication of accounts of the episode. The former is strategy; the latter is the kind of suppression that forfeits the credibility the strategy was meant to protect. Even granting the ADA's premise that protecting funding serves patients, the method it chose damaged the organization's standing more than the funding risk it was avoiding, which is why so many of its own members concluded the calculation was both wrong in principle and incompetent in practice.
How to read it
The clarifying lens the 2015 comparison provides is that principles are only tested when upholding them is costly, and the ADA passed the cheap test a decade ago and is failing the expensive one now. That is not primarily a story about a diabetes group; it is a general truth about institutions, and a warning about what happens to any scientific or advocacy body that becomes dependent on a funder it might need to criticize. The dependence creates a conflict of interest that stays invisible until the moment the funder does something worth criticizing, at which point the organization discovers whether its independence was real or merely affordable.
This analysis takes no position on the federal funding decisions at the root of the dispute, which are legitimately contested. The structural point stands regardless of them: a scientific organization that resolves the funding-versus-independence conflict in favor of funding erodes the credibility that gives its funding a purpose, and it usually pays a reputational price that exceeds whatever it was trying to protect. The members calling for editorial independence to be restored are asking the ADA to recognize that its value was never the money it could protect by staying quiet, but the trust it could only keep by refusing to. Whether the organization can still hear that, forty-five days and one botched apology later, is the actual test in front of it, and it is a harder test than the one it passed in 2015, precisely because this time passing it will cost something.
Primary sources
- STAT's July 31 opinion piece by Adam Marcus and Ivan Oransky of Retraction Watch for the historical comparison to the ADA's 2015 defense of its journal Diabetes in the Mario Saad defamation suit, CEO Charles Henderson's linkage of the organization's conduct to advocating for robust NIH funding, and the argument that fear of jeopardizing funding may explain the suppression.
- STAT's July 28 report for the open letter from more than 200 members demanding the resignations of CEO Charles Henderson and chief scientific and medical officer Rita Kalyani, an independent investigation, a full apology to the five removed researchers, and the restoration of editorial independence at Diabetes Care, plus the ADA's request for patience pending an audit and governance committee report.
- The Scientist and Science/AAAS for the June 5 removal of five researchers by security or police for distributing a Diabetes Care editorial criticizing the administration, Henderson's June 10 video apology naming the five and announcing an independent review, the resignations of senior figures, and researcher Justin Ryder's characterization of the removal as disturbing censorship.
- The ADA's own press releases and updates for Henderson's apology taking responsibility for the missteps, the commissioned independent review, the more-than-155-million-people figure, and the organization's stated continued advocacy for research funding amid federal threats.